BTIG Research Reiterates Neutral Rating for Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)‘s stock had its “neutral” rating reiterated by investment analysts at BTIG Research in a research note issued to investors on Thursday.

TEVA has been the topic of a number of other research reports. Gabelli reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Monday, January 9th. Royal Bank of Canada set a $42.00 price objective on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Monday, January 9th. Guggenheim reaffirmed a “buy” rating and set a $80.00 price objective on shares of Teva Pharmaceutical Industries in a report on Friday, December 23rd. Deutsche Bank AG reaffirmed a “buy” rating and set a $54.00 price objective on shares of Teva Pharmaceutical Industries in a report on Wednesday, December 7th. Finally, Maxim Group decreased their target price on Teva Pharmaceutical Industries from $52.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, January 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $45.14.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) traded up 1.20% during midday trading on Thursday, hitting $31.13. 6,457,334 shares of the stock traded hands. Teva Pharmaceutical Industries has a 52-week low of $30.57 and a 52-week high of $57.52. The company has a market cap of $31.60 billion, a price-to-earnings ratio of 444.71 and a beta of 0.58. The firm’s 50-day moving average is $32.75 and its 200-day moving average is $36.56. Teva Pharmaceutical Industries also saw some unusual options trading on Thursday. Stock investors acquired 422 put options on the company. This represents an increase of approximately 111% compared to the typical volume of 200 put options.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Monday, February 13th. The company reported $1.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.36 by $0.02. Teva Pharmaceutical Industries had a return on equity of 17.46% and a net margin of 1.50%. The company earned $6.25 billion during the quarter, compared to analysts’ expectations of $6.26 billion. During the same quarter in the previous year, the business earned $1.32 earnings per share. The firm’s revenue for the quarter was up 33.0% on a year-over-year basis. Analysts predict that Teva Pharmaceutical Industries will post $4.82 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “BTIG Research Reiterates Neutral Rating for Teva Pharmaceutical Industries Ltd (TEVA)” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/04/21/teva-pharmaceutical-industries-teva-neutral-rating-reaffirmed-at-btig-research-updated.html.

A number of large investors have recently modified their holdings of the stock. Rothschild Investment Corp IL increased its position in Teva Pharmaceutical Industries by 1.5% in the third quarter. Rothschild Investment Corp IL now owns 17,393 shares of the company’s stock worth $800,000 after buying an additional 263 shares in the last quarter. Bank of Montreal Can increased its position in Teva Pharmaceutical Industries by 10.3% in the third quarter. Bank of Montreal Can now owns 412,911 shares of the company’s stock worth $18,998,000 after buying an additional 38,461 shares in the last quarter. Hayek Kallen Investment Management increased its position in Teva Pharmaceutical Industries by 2.0% in the third quarter. Hayek Kallen Investment Management now owns 71,867 shares of the company’s stock worth $3,307,000 after buying an additional 1,381 shares in the last quarter. Trust Co. of Vermont increased its position in Teva Pharmaceutical Industries by 7.9% in the third quarter. Trust Co. of Vermont now owns 15,005 shares of the company’s stock worth $691,000 after buying an additional 1,105 shares in the last quarter. Finally, Heritage Investors Management Corp increased its position in Teva Pharmaceutical Industries by 10.2% in the third quarter. Heritage Investors Management Corp now owns 161,484 shares of the company’s stock worth $7,430,000 after buying an additional 14,922 shares in the last quarter. Hedge funds and other institutional investors own 55.03% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

5 Day Chart for NYSE:TEVA

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply